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Cross-sectional study developed to relate the international normalized ratio (INR), used 
as a parameter to monitor the levels of blood clotting, stability to adherence, age, level 
of education, socioeconomic level, interaction with other drugs, comorbidities, vitamin K 
intake, anticoagulation time and drug cost. 156 patients were included, mean age 57±13 
years, (53.8%) male, 61 (39.1%) had high adherence, 91 (58.3%) medium and 4 (2.6%) 
low adherence to treatment, 117 (75%) had INR stability up to 50% and 39 (25%) ≥ 75%, 
patients with shorter time of anticoagulation presented higher stability, those who spent 
less on the drug remained more stable and had better adherence. It was concluded that 
more than 90% of patients had high and medium adherence and that the anticoagulation 
time and drug cost were the factors related to the anticoagulation stability.
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Adesão farmacológica ao anticoagulante oral e os fatores que 
influenciam na estabilidade do índice de normatização internacional
Este é um estudo transversal, desenvolvido com o objetivo de relacionar a estabilidade do 
índice de normatização internacional (INR), utilizado como parâmetro para monitorar os 
níveis de coagulação do sangue, com adesão, idade, escolaridade, nível socioeconômico, 
interação com outras medicações, comorbidades, ingesta de vitamina K, tempo de 
anticoagulação (ACO) e custo com medicações. Incluíram-se 156 pacientes, idade média 
57±13 anos, 53,8% pertencente ao sexo masculino; 61 (39,1%) tiveram alta adesão, 
91 (58,3%) média e 4 (2,6%) baixa adesão ao tratamento; 117 (75%) apresentaram 
estabilidade do INR de até 50% e 39 (25%) ≥ a 75%; pacientes com menor tempo de 
ACO apresentaram maior estabilidade; aqueles que gastavam menos com a medicação 
permaneciam mais estáveis e com melhor adesão. Concluiu-se que mais de 90% dos 
pacientes apresentaram alta e média adesão referida, e que tempo de anticoagulação e 
custo com a medicação foram os fatores relacionados à estabilidade da ACO.
Descritores: Anticoagulantes; Coeficiente Internacional Normatizado; Monitorização 
Ambulatorial.
Adhesión farmacológica al anticoagulante oral y factores que influyen 
en la estabilidad del índice de estandarización internacional
Se trata de un estudio transversal, desarrollado con el objetivo de relacionar la estabilidad 
del índice de estandarización internacional (INR), utilizado como parámetro para 
monitorizar los niveles de coagulación de la sangre, con adhesión, edad, escolaridad, 
nivel socioeconómico, interacción con otras medicaciones, comorbilidad, ingesta de 
vitamina K, tiempo de anticoagulación (ACO) y costo con medicamentos. Se incluyeron 
156 pacientes, edad promedio 57±13 años, 53,8% perteneciente al sexo masculino; 
61 (39,1%) tuvieron alta adhesión, 91 (58,3%) promedio y 4 (2,6%) baja adhesión al 
tratamiento; 117 (75%) presentaron estabilidad del INR de hasta 50% y 39 (25%) ≥ a 
75%; los pacientes con menor tiempo de ACO presentaron mayor estabilidad; aquellos 
que gastaban menos con la medicación permanecían más estables y con mejor adhesión. 
Se concluyó que más del 90% de los pacientes presentaron adhesión alta y promedio, 
y que el tiempo de anticoagulación y el costo con la medicación fueron los factores 
relacionados a la estabilidad de la ACO.
Descriptores: Anticoagulantes; Relación Normalizada Internacional; Monitoreo 
Ambulatorio.
Introduction
The use of anticoagulant therapy has significantly 
increased in the last decades due to its proven 
effectiveness and safety, besides its numerous 
indications(1). The indications of this therapy include 
prevention and treatment of deep venous thrombosis, 
extensive anterior acute myocardial infarction, prosthetic 
and bioprosthetic heart valves (in the first 3 months), 
atrial fibrillation, intracardiac thrombi and others(2). 
However, anticoagulant therapy instability has been a 
problem since the discovery of cumarinic drugs(3).
Anticoagulation (ACO) stability is related to 
adherence, as well as several other factors, such as age, 
concomitant use of other drugs, comorbidities, genetic 
polymorphisms and vitamin K intake(4). The importance 
of the diet is often cited in educational programs for 
patients in outpatient anticoagulation therapy and 
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various nutrients, especially vitamin K, have been 
remembered in the nutrient-drug interactions with 
coumarin derivatives(3). Vitamin K is an essential cofactor 
for the synthesis of carboxyglutamic acid, a critical step 
in the activation of 4 coagulation factors (II, VII, IX, 
and X) and proteins C and S(5). Although the impact of 
dietary vitamin K intake on long term oral anticoagulation 
has been recognized for 30 years(6), recent prospective 
evidence suggests that this interaction is clinically 
relevant and might be a major independent factor that 
interferes with anticoagulation stability(7).
Drug cost should also be considered as one of 
the causes that interfere in treatment adherence. This 
factor is undoubtedly a great obstacle to adherence 
and, therefore, it should be contextualized mainly in 
developing countries, where access to drugs is often 
limited(8).
Several studies have been conducted for the purpose 
of evaluating the patients’ knowledge of oral anticoagulant 
treatment, its effects and complications(9-10). In this 
context, a review article identified eight instruments in 
the literature. However, these authors emphasize that 
there is little evidence for the selection of a specific 
instrument to actually evaluate the patients’ knowledge 
and therapeutic implications, and that each country 
should validate its own instrument adapted to its 
culture and, in this way, evaluate also this factor as an 
intervention in ACO adherence and stability(11).
Recent studies comparing patients monitored by 
specialists at anticoagulation clinics and monitored under 
systematic education on the anticoagulant therapy show 
a better control of the international normalized ratio 
(INR) within the therapeutic range(12-13). In this context, a 
cross-sectional study that included 52 patients compared 
the effects of education on adherence, knowledge and 
quality of life at two ACO clinics, and found that ACO 
control is associated with adequate adherence and does 
not involve demographic variables, knowledge on the 
utilized therapy or perception of quality of life(14).
The investigation of factors like adherence, age, 
level of education, socioeconomic level, interaction 
with other drugs, comorbidities, vitamin K intake, 
anticoagulation time, drug cost and INR stability remains 
poorly explored in literature.
Considering the large number of patients with precise 
indications of oral anticoagulation and the evidence that, 
even if accompanied by an outpatient clinic, they do not 
reach therapeutic levels of INR, it is essential to identify 
factors that may be related to compliance and, hence, to 
instability of anticoagulation.
Objective
To evaluate the factors that can interfere in 
treatment adherence and INR stability.
Methods
A cross-sectional correlational study was developed 
at an ACO outpatient clinic of a federal public teaching 
hospital in southern Brazil, from August 2007 to January 
2008. The study included consecutively, through a 
convenience sample, chronically anticoagulated patients 
with any clinical indication; of both genders and ≥ 18 
years of age; taking Warfarin 5mg or Marcoumar 3mg. 
The study excluded patients with cognitive deficit or 
neurological sequelae that could affect the way the 
instrument is completed. The study was approved by the 
institution’s ethics committee, protocol number 07334. 
The patients who agreed to participate in the study 
signed the Informed Consent Form.
The Morisky Adherence Scale was applied for the 
evaluation, comprising four Likert-type questions with 
a score ranging from zero (high adherence) to four 
(low adherence). The patient was classified in the high 
adherence level group when the answers to all questions 
were negative and in the medium adherence level group 
with one or two affirmative answers. However, with three 
or four affirmative answers, the patient was classified in 
the low adherence level group(15).
This scale has been used in Brazil in different 
scenarios. Recently, it has been used in hypertensive 
patients to assess adherence to drug and non-
pharmacological treatment(16) and also in patients on 
chronic oral anticoagulation(17). Moreover, this same 
scale was also used to assess the validity of four 
indirect methods of measuring medication adherence in 
hypertensive patients(18).
The INR stability was calculated using the INR 
number within the therapeutic range divided by the 
collected INR number (for example, a patient with an 
INR target of 2.0-3.0 - INR1 = 2.0, INR2 = 1.5, INR3 = 
2.4, INR4 = 1.85, INR5 = 3.0: 3 values within the target 
level, presented 60% stability). INR has been proposed 
as a way to eliminate inter-laboratory differences in 
test results caused by the use of thromboplastins with 
different sensitivities. The INR is calculated by raising the 
prothrombin time ratio (PTR; the patient’s prothrombin 
time divided by a reference normal prothrombin time) 
to the power of a coefficient known as the international 
sensitivity index (ISI). This coefficient relates the 
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sensitivity for monitoring warfarin therapy of a given 
thromboplastin to the sensitivity of the World Health 
Organization’s first primary international reference 
preparation of thromboplastin, which was assigned an 
ISI of 1.0(19). An instrument was elaborated for this 
study with clinical and demographic variables. As it was 
not possible to measure the exact amount of vitamin K 
intake, this information was estimated considering the 
number of times the patients consumed vitamin K-rich 
foods in the week prior to the INR test, according to 
what they reported on the clinical evaluation form.
Major bleeding event was defined as a fatal and 
symptomatic one; and/or decrease in hemoglobin of at 
least 3.0 g/dL, and/or bleeding requiring transfusion of 
two or more units of red blood cells. Any other bleeding 
considered significant and not meeting the criteria of 
major bleeding was considered minor bleeding(20).
Data Analysis
The analyses were performed using Statistical 
Package for Social Sciences 14.0. Continuous variables 
were expressed as mean ± standard deviation to data 
of normal distribution and as median and interquartile 
interval to non-parametric data. Categorical variables 
are expressed as percentages. The Mann-Whitney test 
was utilized in non-parametric data associations. A two-
tailed P value below 0.05 was considered statistically 
significant. Considering 80% power and 5% significance 
level to detect a 23% stability difference among patients 
with good and bad reported adherence, it was necessary 
to include 156 patients.
Results
This study included 156 chronically anticoagulated 
patients. Mean age was 57.4±13 years (ranging 
between 25 and 82 years), 84 (53.8%) of the patients 
were male and presented a median 2 (1-4) years of 
level of education, and most were inactive 121 (77.6%). 
The average monthly income was 633±454 U$ and the 
median monthly cost of anticoagulation was 8.3 (5.6-11). 
The main indication for oral anticoagulation use in the 
studied population was atrial fibrillation in 53 (34.2%) 
patients. The median duration of anticoagulation was 
27.5 (10-52) months, ranging from shorter than 1 
month to a maximum of 216 months. A median duration 
of anticoagulation group was 12 (3-31) months. The 
most common anticoagulant was Warfarin 135 (86.5%), 
with a maximum dose of 93mg per month. In those 
patients using acetylsalicylic acid, 65 (41.9%) ingested 
100 mg and 5 (3.2%) ingested 200mg. Table 1 shows 
these characteristics.
Age (years)* 57.4±13
Gender (male)† 84 (53.8)
Level of education (years)‡ 2 (1-4)
Marital status (married)† 120 (76.9)
Lives with relative† 144 (92,9)
Occupation†
Full time 35 (22.4)
Retired 121 (77.6)
Monthly income U$* 633±454
Monthly cost of anticoagulant U$‡ 8.3 (5.6-11)
Anticoagulation indication†
Atrial fibrillation 53 (34)
Mitral mechanical prosthesis 45 (28.8)
Aortic mechanical prosthesis 43 (27.6)
Others 15 (9.6)
Anticoagulation time (months)‡ 27.5 (10-52)
Group time (months)‡ 12 (3-31)
Anticoagulant drug†
Warfarin 5mg 135 (86.5)
Marcoumar 3mg 21 (13.5)
Drugs that interfere†
Acetylsalicylic acid 100mg 65 (41.9)
Others 102 (63.8)
Table 1 - Demographic and clinical characteristics of 
anticoagulated patients. Porto Alegre 2008
*Values expressed as mean ± standard deviation, †n (%) categorical 
variables, ‡median (25 and 75 percentiles)
Table 2 shows adherence to the pharmacological 
treatment classified as high, medium and low adherence. 
It is noted that more than 90% of patients are classified 
between medium and high adherence.
Table 2 – Anticoagulated patients and Morisky Adherence 
Scale. Porto Alegre, 2008
Adherence Patients answered “yes” in: N(156) %
High 0 (no question) 61 39.1
Medium 1 question 42 26.9
2 questions 49 31.4
Low 3 questions 4 2.6
4 questions 0 0
* Categorical variables n(%).
Regarding INR stability, 117 (75%) patients showed 
with stability up to 50% and 39 (25%) presented stability 
of 75% or above. When stability was related to factors 
like adherence, age, level of education, socioeconomic 
level, interaction with other drugs, comorbidities 
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and vitamin K intake, no significant association was 
observed. Patients with shorter anticoagulation time 
presented greater stability than longtime anticoagulated 
patients. The monthly cost was another factor related 
to INR stability, with patients who spent less with the 
drug remaining more stable (P<0.05). Table 3 shows 
these data.
Table 3 - Factors related to the INR stability of 
anticoagulated patients. Porto Alegre, 2008
Stability Stability
P†
≥ 75% up to 50%
Anticoagulation time (months)* 18 (7-36) 36 (12-60) < 0.05
Monthly cost U$* 6.6 (5-10.5) 8.3 (5.6-11) < 0.05
* Values expressed as median (percentage: 25; percentage: 75). † Tests 
utilized: Mann-Whitney
Sixty-eight (42.5%) of the patients evaluated failed 
to take the anticoagulant at least once, and 57 (83.8%) 
of them presented up to 50% (P <0.05) stability.
Regarding the occurrence of previous complications 
(hemorrhagic or thromboembolic events), 4 (2.6%) 
patients presented thromboembolic events during the 
treatment. Hemorrhagic events were the most prevalent, 
41 (26.5%) of the patients presented mild bleeding and 
17 (11%) heavier bleeding. When the occurrence of these 
events was related to adherence to the pharmacological 
treatment, use of drugs that interact with cumarinic 
drugs or occurring during the ACO time, no significant 
relation was found.
Regarding the factors that influenced adherence 
to the pharmacological treatment, a significant 
association was found between drug cost and adherence 
to pharmacological treatment. Among patients who 
presented satisfactory adherence, 61 (38.12%) spent a 
median of U$7.8 (5.5-9.4) on the drug and patients that 
presented low or medium adherence spent median of 
U$10 (6.7-11) (P<0.05) with the anticoagulant.
Discussion
This study demonstrated that little over half the 
patients presented medium or low reported adherence. 
Even linked with a specific outpatient clinic and receiving 
regular monitoring, only 39 (25%) presented a stability 
of 75% or higher. The factors related to stability were: 
anticoagulation time and drug cost. In addition, a 
significant association was found between drug cost 
and treatment adherence. There was a small number 
of thromboembolic events, although some cases of 
underanticoagulation were registered. Bleeding episodes 
were mostly minor.
The time the patients remained within the target 
INR was shorter than the time published at the seventh 
conference of the American College of Chest Physicians 
about antithrombotic and thrombolytic treatment, 
from 2004, which reports that studies with target INR 
achieved 50 to 70% of the time, approximately(3). 
However, the low percentage of patients who achieved 
the target INR in this study agrees with the data in 
the international literature. Even studies conducted in 
developed countries, with a more educated population, 
demonstrate low stability rates(21). Therefore, the fact of 
belonging to a developed country or having a higher level 
of education does not seem to matter, as the problem of 
indication for chronic treatment with frequent monitoring 
seems to be similar in all patients.
Although some studies in the literature have 
demonstrated that anticoagulation stability is related 
to factors like adherence, age, level of education, 
socioeconomic level, interaction with other drugs, 
comorbidities and vitamin K intake(4,22), no association 
with these factors was found in this study. These data 
were also recently demonstrated in a study conducted 
in specialized outpatient clinics in Brazil(17). It can be 
concluded that this is due to differences in the evaluation 
methods that were used in studies demonstrating the 
impact of adherence on INR stability. Other evaluation 
instruments were also utilized, such as electronic 
devices(13).
The mean age of patients included in the study was 
57 years, a different characteristic from what was found 
in other studies that demonstrate that elderly patients, 
over 70 years old, have less adequate control of ACO, 
with bleeding as the most frequent complications in this 
population(23). In this scenario, education and systematic 
nursing monitoring has shown satisfactory results in 
the reduction of thrombotic events or bleedings, which 
involves improved quality of life for these patients(12).
Many patients used one or more drugs interacting 
with warfarin, but the occurrence of complications or 
INR instability was not attributed to the concomitant 
use of these drugs, as the most frequent drugs utilized 
by the patients (propranolol, simvastatin, omeprazole, 
amiodarone, etc.), except for acetylsalicylic acid, were 
classified as having little probability of interaction, 
according to a systematic review published in 2005. This 
review also demonstrated that, although the number 
of drugs that interact with warfarin keeps increasing, 
only small studies have been conducted so far(24). Co-
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administration of acetylsalicylic acid (aspirin) and 
warfarin increases the risk of bleeding. The mechanisms 
of this adverse interaction are antiplatelet effects, gastric 
mucosal damage and a hypothrombinemic response to 
warfarin (with an aspirin dosage of 2 to 4 g per day)(25).
Some randomized clinical trials on diet strategy 
have demonstrated the impact of changes in vitamin 
K intake on ACO control(3-4,22). As our study is an 
observational study and does not regard diet strategy, it 
was impossible to actually demonstrate the influence of 
vitamin K intake on the stability of these patients.
Anticoagulation time and drug cost were related 
to INR stability, with short-time anticoagulated patients 
and patients who spent less on the drug remaining 
more stable. However, no study was found in literature 
that has related these factors to anticoagulation 
stability. The reason why short-time anticoagulated 
patients presented higher stability can be related to 
more intensive monitoring, which is performed at the 
beginning of the treatment with anticoagulation, when 
more dose adjustments are required. The lack of 
financial resources was the main reason to interrupt 
treatment, which contributed to greater instability of the 
patients. However, these are data from the time of the 
interview and may not reflect the true influence of the 
lack of resources throughout the treatment.
Few patients presented complications. 
Hemorrhagic complications, especially intracranial and 
gastrointestinal types, are most frequently expected 
when oral anticoagulation is prescribed(26). According to 
data presented in an international consensus, the main 
determinants of bleeding are INR oscillation, INR values 
above five and concomitant use of other drugs (especially 
platelet anti-aggregating substance). Despite this, the 
annual rates of clinically relevant bleeding (intracerebral 
and gastrointestinal tract hemorrhage are around 1.3% 
when the INR remains within the therapeutic range from 
two to three, which corresponds to approximately the 
value found in this study(27).
Patients who presented satisfactory adherence 
spent less on the drug compared with those who 
presented medium or low adherence. We found results 
similar to another classical study that attempted to 
evaluate the drug cost impact on adherence to the 
pharmacological treatment. In this study, the main factor 
reported for non-adherence to treatment by elderly 
people was the high cost of the drug. Besides, the cost 
of drugs prescribed to non-adherent patients was on 
average twice as high as the cost of drugs prescribed to 
patients who adhered to the treatment(8). This factor is 
undoubtedly a great obstacle to adherence and should 
be one of the contextualized aspects, especially in 
developing countries.
However, some studies that report high non-
adherence rates do not refer to drug availability. For 
example, a study published in 2009 about factors 
associated to patients’ noncompliance with hypertension 
treatment according to the Morisky-Green protocol 
found that 86.76% did not comply with the medication 
regimen and the reasons reported for non-adherence to 
medication included: cannot tell the reason (P=0.006), 
associated diseases (P=0.049) and alcohol consumption 
(P=0.013)(28). Beyond the question of costs, other factors 
may be associated with non-adherence when comparing 
treatments of continued use in chronic disease.
Therefore, only by knowing the forms of access to 
drugs will we be able to ask questions about treatment 
adherence. However, recent studies that compare 
patients under monitoring by specialized professionals at 
anticoagulation clinics and monitoring under systematic 
education have presented positive results in terms of 
improved adherence and patient’s knowledge on the 
adopted therapy(12-13).
Study limitations
The Morisky adherence scale is widely utilized 
to evaluate adherence to drug therapy, but we found 
some limitations when applying it. This test tends to 
overestimate non-adherence and does not provide the 
patient with an opportunity to express his/her difficulties 
and understanding related to the treatment. Therefore, 
the development of other instruments to evaluate 
adherence is required, especially in patients who use oral 
anticoagulants. Another factor identified as a limitation 
was the form of evaluating vitamin K intake, because 
we know that an inconsistent intake can contribute to 
changes in INR levels. Other studies with an appropriate 
design to assess a combination with other factors, 
such as alcohol consumption and presence of genetic 
polymorphisms, may yield more conclusive results.
Conclusions
Over 90% of the patients presented high and 
medium reported adherence. Anticoagulation time and 
drug cost were the factors with the highest correlation 
with ACO stability.
Based on the results of this study, it was possible 
to demonstrate that factors like adherence, age, level 
of education, socioeconomic level, interaction with 
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other drugs, comorbidities and vitamin K intake did not 
influence INR stability. However, the results show that 
anticoagulation time and economic difficulties constitute 
barriers to anticoagulation treatment adherence and that 
some professionals often undervalue the unavailability 
of access to the drug. Knowing these data may permit 
the development of specific strategies in the scenario 
of an outpatient clinic service, elaborated by nurses, 
further qualifying nurse monitoring and, consequently, 
improving treatment adherence, quality, understanding, 
patient care, and minimizing the risk of thromboembolic 
and hemorrhagic complications.
Considering the high number of patients with a 
precise indication for oral anticoagulation and who 
do not achieve therapeutic levels of INR even when 
monitored at a specialized outpatient clinic, it is essential 
to identify clinical predictors of underanticoagulation 
and overanticoagulation. New studies are required to 
identify and remove obstacles to adequate and safe 
chronic anticoagulation.
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